Yutiq is a drug owned by Alimera Sciences Inc. It is protected by 10 US drug patents filed from 2018 to 2022. Out of these, 2 drug patents are active and 8 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 12, 2028. Details of Yutiq's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7998108 | Injector apparatus and method of use |
Jan, 2028
(2 years from now) | Active |
| US8871241 | Injectable sustained release delivery devices |
Aug, 2027
(1 year, 9 months from now) | Active |
| US8574659 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
Apr, 2020
(5 years ago) |
Expired
|
| US9192579 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
Apr, 2020
(5 years ago) |
Expired
|
| US9849085 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
Apr, 2020
(5 years ago) |
Expired
|
| US6375972 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
Apr, 2020
(5 years ago) |
Expired
|
| US8574613 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
Apr, 2020
(5 years ago) |
Expired
|
| US8252307 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Jun, 2019
(6 years ago) |
Expired
|
| US6548078 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Mar, 2019
(6 years ago) |
Expired
|
| US6217895 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Mar, 2019
(6 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Yutiq's patents.
Latest Legal Activities on Yutiq's Patents
Given below is the list of recent legal activities going on the following patents of Yutiq.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent
Critical | 01 Jan, 2024 | US9192579 |
| Maintenance Fee Reminder Mailed
Critical | 17 Jul, 2023 | US9192579 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 01 Feb, 2023 | US7998108 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 07 Apr, 2022 | US7998108 |
| Expire Patent
Critical | 31 Jan, 2022 | US9849085 |
| Expire Patent
Critical | 13 Dec, 2021 | US8574613 |
| Expire Patent
Critical | 13 Dec, 2021 | US8574659 |
| Maintenance Fee Reminder Mailed
Critical | 16 Aug, 2021 | US9849085 |
| Maintenance Fee Reminder Mailed
Critical | 28 Jun, 2021 | US8574613 |
| Maintenance Fee Reminder Mailed
Critical | 28 Jun, 2021 | US8574659 |
FDA has granted several exclusivities to Yutiq. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Yutiq, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Yutiq.
Exclusivity Information
Yutiq holds 1 exclusivities. All of its exclusivities have expired in 2021. Details of Yutiq's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 12, 2021 |
US patents provide insights into the exclusivity only within the United States, but
Yutiq is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Yutiq's family patents as well as insights into
ongoing legal events
on those patents.
Yutiq's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Yutiq's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 12, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Yutiq Generic API suppliers:
Fluocinolone Acetonide is the generic name for the brand Yutiq. 27 different companies have already filed for the generic of Yutiq, with Taro having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Yutiq's generic
Alternative Brands for Yutiq
Yutiq which is used for treating chronic non-infectious uveitis affecting the posterior segment of the eye., has several other brand drugs in the same treatment category and using the same active ingredient (Fluocinolone Acetonide). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Bausch And Lomb |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Fluocinolone Acetonide. Given below is the list of those drugs and companies owning them.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Fluocinolone Acetonide, Yutiq's active ingredient. Check the complete list of approved generic manufacturers for Yutiq
About Yutiq
Yutiq is a drug owned by Alimera Sciences Inc. It is used for treating chronic non-infectious uveitis affecting the posterior segment of the eye. Yutiq uses Fluocinolone Acetonide as an active ingredient. Yutiq was launched by Alimera Sciences Inc in 2018.
Approval Date:
Yutiq was approved by FDA for market use on 12 October, 2018.
Active Ingredient:
Yutiq uses Fluocinolone Acetonide as the active ingredient. Check out other Drugs and Companies using Fluocinolone Acetonide ingredient
Treatment:
Yutiq is used for treating chronic non-infectious uveitis affecting the posterior segment of the eye.
Dosage:
Yutiq is available in implant form for intravitreal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.18MG | IMPLANT | Prescription | INTRAVITREAL |